Business Context and Reporting Period
Company: Bristol-Myers Squibb Company (BMY)
Filing Type: Form 8-K (Current Report)
Reporting Date: October 31, 2019
Event: Announcement of financial results for the third quarter of 2019.
Key Financial Metrics
The provided filing text serves as a cover document referencing an external press release (Exhibit 99.1) and supplemental website information (Exhibit 99.2). The text of this 8-K filing does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the incorporated exhibits for these figures.
Material Changes
The filing text does not contain specific data regarding material changes versus the prior comparable period. It only confirms that the Company issued a press release announcing Q3 2019 results.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates by reference the Earnings Press Release and supplemental information posted on the Company's website, which would contain management commentary, guidance, and outlook.
Risks and Contingencies: No specific risks or contingencies are detailed in the text of this 8-K form; such disclosures are contained within the referenced exhibits.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated October 31, 2019) for actual Q3 2019 revenue, net income, and earnings per share figures.
- Access Exhibit 99.2 (Supplemental Information) for detailed segment performance and non-GAAP reconciliations.
- Verify the Company's forward-looking guidance and any updates to full-year 2019 projections in the press release.
- Confirm the status of outstanding debt securities (1.000% Notes due 2025 and 1.750% Notes due 2035) listed in the filing.